Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Income towards Parent Company (2020 - 2025)

Oncology Institute (TOI) has disclosed Income towards Parent Company for 6 consecutive years, with -$16.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income towards Parent Company fell 2.43% year-over-year to -$16.5 million, compared with a TTM value of -$66.3 million through Sep 2025, up 5.63%, and an annual FY2024 reading of -$64.7 million, up 22.16% over the prior year.
  • Income towards Parent Company was -$16.5 million for Q3 2025 at Oncology Institute, up from -$17.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $19.3 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
  • Average Income towards Parent Company over 5 years is -$11.0 million, with a median of -$15.5 million recorded in 2024.
  • Peak annual rise in Income towards Parent Company hit 2869.26% in 2021, while the deepest fall reached 2108.96% in 2021.
  • Year by year, Income towards Parent Company stood at -$10.2 million in 2021, then decreased by 8.38% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then grew by 29.71% to -$13.2 million in 2024, then decreased by 25.2% to -$16.5 million in 2025.
  • Business Quant data shows Income towards Parent Company for TOI at -$16.5 million in Q3 2025, -$17.0 million in Q2 2025, and -$19.6 million in Q1 2025.